Beam Therapeutics

BEAM THERAPEUTICS INC

Beam Inc.

NYSE

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Beam Therapeutics Inc

BEAM - United States dollar

Beam Global

Beamr Imaging Ltd

BEAM COMM HLDGS LTD by BEAM COMMUNICATIONS HLDGS LTD.

BEAMZ INTERACTIVE INC by Beamz Interactive Inc

Beamz Interactive Inc

Earnings

Press Releases

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

News

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Health Care

General

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Legal

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical  Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

BEAM

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Cidara Therapeutics

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Cogent Biosciences

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Amicus Therapeutics

GRAIL

IDEAYA Biosciences

Immunovant

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Veracyte

Xenon Pharmaceuticals Inc. - Common Shares

Comments

Beam Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL